222 related articles for article (PubMed ID: 19375625)
1. Overview of pivotal studies for prostate cancer risk reduction, past and present.
Andriole GL
Urology; 2009 May; 73(5 Suppl):S36-43. PubMed ID: 19375625
[TBL] [Abstract][Full Text] [Related]
2. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological approaches to reducing the risk of prostate cancer.
Rittmaster RS; Fleshner NE; Thompson IM
Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
[TBL] [Abstract][Full Text] [Related]
4. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
[TBL] [Abstract][Full Text] [Related]
5. High-grade prostate cancer and finasteride.
Lebdai S; Bigot P; Azzouzi AR
BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
[TBL] [Abstract][Full Text] [Related]
6. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer: a serious disease suitable for prevention.
Fitzpatrick JM; Schulman C; Zlotta AR; Schröder FH
BJU Int; 2009 Apr; 103(7):864-70. PubMed ID: 19302133
[TBL] [Abstract][Full Text] [Related]
8. Update on prostate cancer chemoprevention.
Lowe JF; Frazee LA
Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
[TBL] [Abstract][Full Text] [Related]
9. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
Reed AB; Parekh DJ
Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of prostate cancer.
Stephenson AJ; Abouassaly R; Klein EA
Urol Clin North Am; 2010 Feb; 37(1):11-21, Table of Contents. PubMed ID: 20152515
[TBL] [Abstract][Full Text] [Related]
11. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
12. Update on chemoprevention for prostate cancer.
Strope SA; Andriole GL
Curr Opin Urol; 2010 May; 20(3):194-7. PubMed ID: 20216317
[TBL] [Abstract][Full Text] [Related]
13. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
[TBL] [Abstract][Full Text] [Related]
14. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
[TBL] [Abstract][Full Text] [Related]
15. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of prostate cancer.
Walsh PC
N Engl J Med; 2010 Apr; 362(13):1237-8. PubMed ID: 20357287
[No Abstract] [Full Text] [Related]
17. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
18. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention.
Canby-Hagino E; Hernandez J; Brand TC; Thompson I
Eur Urol; 2007 Jan; 51(1):27-33. PubMed ID: 17030406
[TBL] [Abstract][Full Text] [Related]
19. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.
Ravish IR; Nerli RB; Amarkhed SS
Arch Androl; 2007; 53(1):17-20. PubMed ID: 17364459
[TBL] [Abstract][Full Text] [Related]
20. Effect of finasteride on risk of prostate cancer: how little we really know.
Rubin MA; Kantoff PW
J Cell Biochem; 2004 Feb; 91(3):478-82. PubMed ID: 14755678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]